DF
NBIX icon

Donoghue Forlines’s Neurocrine Biosciences NBIX Stock Holding History

Donoghue Forlines’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,216
Closed -$255K – 207
2024
Q3 		$255K Sell
2,216
-10,955
-83% -$1.5M 0.07% 210
2024
Q2 		$1.81M Buy
13,171
+11,320
+612% +$1.55M 0.52% 35
2024
Q1 		$255K Buy
1,851
+303
+20% +$41.4K 0.07% 211
2023
Q4 		$204K Buy
+1,548
New +$178K 0.06% 213
2023
Q3 		– Sell
-3,174
Closed -$299K – 266
2023
Q2 		$299K Buy
+3,174
New +$310K 0.09% 225
2023
Q1 		– Sell
-1,727
Closed -$206K – 246
2022
Q4 		$206K Sell
1,727
-233
-12% -$27.3K 0.07% 218
2022
Q3 		$208K Buy
+1,960
New +$199K 0.08% 226
2021
Q1 		– Sell
-6,713
Closed -$643K – 272
2020
Q4 		$643K Buy
+6,713
New +$648K 0.12% 186

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Donoghue Forlines's NBIX Position: Q4 2024 in Review

Donoghue Forlines sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 2,216 shares — an estimated $255K sold.

Donoghue Forlines first reported a position in NBIX in Q4 2020 and held it in 8 quarters. The position peaked at $1.81M in Q2 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Donoghue Forlines reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Donoghue Forlines sold 2,216 Neurocrine Biosciences shares in Q4 2024, an estimated $255K.
  • Donoghue Forlines first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 8 quarters.
  • Donoghue Forlines's Neurocrine Biosciences position peaked at $1.81M in Q2 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Donoghue Forlines's 13F filing for Q4 2024, filed 17 Jan 2025.